$KALV
KalVista Pharmaceuticals, Inc.

2016 Q2 Form 10-Q Financial Statement

#000156459016024180 Filed on August 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q4
Revenue $314.0K $667.0K
YoY Change 3040.0% 6570.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.600M $1.320M
YoY Change 122.22% 67.09%
% of Gross Profit
Research & Development $947.0K $4.260M
YoY Change -78.96% 40.59%
% of Gross Profit
Depreciation & Amortization $0.00 $30.00K
YoY Change -100.0% 200.0%
% of Gross Profit
Operating Expenses $5.400M $4.192M
YoY Change -4.83% 9.59%
Operating Profit
YoY Change
Interest Expense -$390.0K -$90.00K
YoY Change 129.41% -83.93%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$7.350M -$5.660M
YoY Change -18.42% 20.17%
Income Tax
% Of Pretax Income
Net Earnings -$4.869M -$2.599M
YoY Change -45.97% -44.87%
Net Earnings / Revenue -1550.64% -389.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.910M -$3.198M
COMMON SHARES
Basic Shares Outstanding 26.32M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.80M $53.70M
YoY Change -43.73% 1276.92%
Cash & Equivalents $21.76M $53.72M
Short-Term Investments
Other Short-Term Assets $1.100M $1.200M
YoY Change -31.25% 71.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.67M $54.95M
YoY Change -63.18% 1097.84%
LONG-TERM ASSETS
Property, Plant & Equipment $74.00K $805.0K
YoY Change -81.5% 347.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $991.0K
YoY Change -50.0% 453.63%
Total Long-Term Assets $13.34M $1.846M
YoY Change 2122.67% -10.26%
TOTAL ASSETS
Total Short-Term Assets $24.67M $54.95M
Total Long-Term Assets $13.34M $1.846M
Total Assets $38.01M $56.79M
YoY Change -43.78% 754.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $187.0K $1.460M
YoY Change -90.65% 42.58%
Accrued Expenses $1.713M $1.327M
YoY Change 0.76% -17.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.500M
YoY Change -100.0% -65.91%
Total Short-Term Liabilities $1.929M $4.271M
YoY Change -54.07% -39.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.200M
YoY Change -100.0% 52.38%
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0% -95.0%
Total Long-Term Liabilities $0.00 $3.300M
YoY Change -100.0% -19.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.929M $4.271M
Total Long-Term Liabilities $0.00 $3.300M
Total Liabilities $1.971M $7.481M
YoY Change -76.25% -33.61%
SHAREHOLDERS EQUITY
Retained Earnings -$86.58M -$72.62M
YoY Change 52.01%
Common Stock $122.6M $121.9M
YoY Change 3292.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$37.11M $49.31M
YoY Change
Total Liabilities & Shareholders Equity $38.01M $56.79M
YoY Change -43.78% 754.77%

Cashflow Statement

Concept 2016 Q2 2015 Q4
OPERATING ACTIVITIES
Net Income -$4.869M -$2.599M
YoY Change -45.97% -44.87%
Depreciation, Depletion And Amortization $0.00 $30.00K
YoY Change -100.0% 200.0%
Cash From Operating Activities -$7.260M -$5.060M
YoY Change 12.73% 16.86%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K -$380.0K
YoY Change -12.5% 375.0%
Acquisitions
YoY Change
Other Investing Activities $180.0K -$720.0K
YoY Change
Cash From Investing Activities $120.0K -$1.090M
YoY Change -250.0% 1262.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.500M 0.000
YoY Change -106.55% -100.0%
NET CHANGE
Cash From Operating Activities -7.260M -5.060M
Cash From Investing Activities 120.0K -1.090M
Cash From Financing Activities -4.500M 0.000
Net Change In Cash -11.64M -6.150M
YoY Change -118.71% 13.47%
FREE CASH FLOW
Cash From Operating Activities -$7.260M -$5.060M
Capital Expenditures -$70.00K -$380.0K
Free Cash Flow -$7.190M -$4.680M
YoY Change 13.05% 10.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26335775
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26335775
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86577000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
122586000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
27000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
947000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
991000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1929000
us-gaap Net Income Loss
NetIncomeLoss
-14196000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11722606
CY2016Q2 us-gaap Assets
Assets
38007000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
187000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1713000
CY2015Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1455000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
29000
CY2015Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
3154000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42000
CY2016Q2 us-gaap Liabilities
Liabilities
1971000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
36036000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38007000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7000
CY2016Q2 us-gaap Restructuring Charges
RestructuringCharges
3420000
us-gaap Interest Expense
InterestExpense
1005000
CY2015Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3177000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3177000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
552000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
65000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
23000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
259000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
183000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-62000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
680000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
155000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-520000
cbyl Non Cash Interest Income Expense
NonCashInterestIncomeExpense
-58000
cbyl Non Cash Interest Income Expense
NonCashInterestIncomeExpense
-157000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
83000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
758000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-59000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1273000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
793000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
386000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
59000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12344000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10490000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000
cbyl Gains Losses On Extinguishment Of Loan Payable
GainsLossesOnExtinguishmentOfLoanPayable
-250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-412000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
924000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-259000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
149000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
68084000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
4500000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4498000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
72233000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16904000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
61484000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3897000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65381000
us-gaap Interest Paid
InterestPaid
606000
us-gaap Interest Paid
InterestPaid
45000
cbyl Transfer Of Long Term Deposits To Property And Equipment
TransferOfLongTermDepositsToPropertyAndEquipment
824000
cbyl Conversion Of Warrant Amount Converted
ConversionOfWarrantAmountConverted
347000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
39556000
cbyl Non Cash Increase Of Accrual For Deferred Public Offering Costs
NonCashIncreaseOfAccrualForDeferredPublicOfferingCosts
175000
cbyl Noncash Derivative Liability Related To Convertible Promissory Notes At Issuance
NoncashDerivativeLiabilityRelatedToConvertiblePromissoryNotesAtIssuance
1196000
cbyl Noncash Or Part Noncash Beneficial Conversion Feature Of Convertible Promissory Notes
NoncashOrPartNoncashBeneficialConversionFeatureOfConvertiblePromissoryNotes
519000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of the interim condensed financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to common stock, stock-based compensation expense, warrant liabilities, accruals, derivative liability, deferred tax valuation allowance and revenue recognition. Management bases its estimates on historical experience or on various other assumptions, including information received from its service providers, which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company invests its excess cash in money market accounts. The Company&#8217;s cash and cash equivalents are held by a single financial institution and all cash is held in the United States. Such deposits may, at times, exceed federally insured limits. The Company has not recognized any losses during the periods presented and management does not believe that the Company is exposed to significant credit risk from its cash and cash equivalents.</p></div>
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Embedded Derivatives Related to Convertible Promissory Notes</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e. host) are accounted for and valued as a separate financial instrument. The Company evaluated the terms and features of the convertible promissory notes issued in September 2014 and February 2015 and identified embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion features (see Note 7 for a description of the conversion features).</p></div>
CY2016Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2004-03-26
us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2016-04-15
CY2016Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
14
CY2016Q2 cbyl Number Of Employees
NumberOfEmployees
17
CY2016Q2 us-gaap Severance Costs1
SeveranceCosts1
300000
CY2016Q2 us-gaap Severance Costs1
SeveranceCosts1
700000
CY2016Q2 cbyl Payment Of Termination Fees
PaymentOfTerminationFees
2450000
CY2016Q1 cbyl Number Of Consecutive Business Period
NumberOfConsecutiveBusinessPeriod
P30D
CY2016Q2 cbyl Number Of Consecutive Business Period
NumberOfConsecutiveBusinessPeriod
P10D
CY2016Q1 cbyl Common Stock Minimum Bid Price
CommonStockMinimumBidPrice
1.00
CY2016Q1 cbyl Initial Period Allowed To Regain Compliance With Listing Qualifications
InitialPeriodAllowedToRegainComplianceWithListingQualifications
P180D
CY2016Q1 cbyl Minimum Bid Price Per Share Required To Regain Compliance With Listing Qualifications
MinimumBidPricePerShareRequiredToRegainComplianceWithListingQualifications
1.00
CY2016Q2 cbyl Minimum Bid Price Per Share Regained Compliance With Listing Qualifications
MinimumBidPricePerShareRegainedComplianceWithListingQualifications
1.00
cbyl Regain Compliance With Listing Qualifications Period End Date
RegainComplianceWithListingQualificationsPeriodEndDate
2016-09-12
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In March 2015, the Company’s board of directors and stockholders approved a 4-for-1 reverse stock split of the Company’s common and preferred stock. The Company filed an amendment to its certificate of incorporation effecting the reverse stock split on March 13, 2015. All share and per share amounts contained in these financial statements and notes thereto, have been adjusted retroactively to reflect the reverse stock split.
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2015Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
105000000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
0
CY2016Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
36794000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53675000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1433000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
628000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
94000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
727000
CY2015Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
110000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
507000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
218000
CY2015Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
48000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
37000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
97000
CY2016Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
180000
CY2016Q2 cbyl Accrued Legal Expenses
AccruedLegalExpenses
727000
CY2015Q4 cbyl Accrued Legal Expenses
AccruedLegalExpenses
77000
CY2016Q2 cbyl Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
153000
CY2015Q4 cbyl Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
338000
CY2016Q2 cbyl Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
529000
CY2015Q4 cbyl Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
185000
cbyl Operating Leases Income Statement Monthly Sublease Revenue
OperatingLeasesIncomeStatementMonthlySubleaseRevenue
16000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
0
CY2016Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
332000
CY2016Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
312000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37000
CY2016Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
800000
CY2016Q2 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
cbyl Additional Period Allowed To Regain Compliance With Listing Qualifications
AdditionalPeriodAllowedToRegainComplianceWithListingQualifications
P180D

Files In Submission

Name View Source Status
0001564590-16-024180-index-headers.html Edgar Link pending
0001564590-16-024180-index.html Edgar Link pending
0001564590-16-024180.txt Edgar Link pending
0001564590-16-024180-xbrl.zip Edgar Link pending
cbyl-10q_20160630.htm Edgar Link pending
cbyl-20160630.xml Edgar Link completed
cbyl-20160630.xsd Edgar Link pending
cbyl-20160630_cal.xml Edgar Link unprocessable
cbyl-20160630_def.xml Edgar Link unprocessable
cbyl-20160630_lab.xml Edgar Link unprocessable
cbyl-20160630_pre.xml Edgar Link unprocessable
cbyl-ex311_8.htm Edgar Link pending
cbyl-ex312_7.htm Edgar Link pending
cbyl-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending